Sou Hu Cai Jing·2025-08-19 02:38Core Viewpoint - JD Health's stock price reached a 250-day high, driven by strong half-year performance and increased interest in internet healthcare stocks, particularly within the Hong Kong Stock Connect Medical ETF [1] Financial Performance - JD Health reported a revenue of approximately 35.29 billion yuan for H1 2025, representing a year-on-year increase of 24.5% [1] - Revenue from pharmaceuticals and health products was 29.3 billion yuan, up 22.7% year-on-year, while digital marketing and other revenues reached 6 billion yuan, growing by 34.4% year-on-year [1] - The company's profit exceeded expectations due to strong pharmaceutical sales and significant growth in advertising revenue, leading to an improvement in gross margin by 1.6% year-on-year [1] User Engagement and Market Position - As of H1 2025, JD Health's active user base surpassed 200 million, with an average of over 500,000 online consultations per day [1] - The number of third-party merchants exceeded 150,000, an increase of over 50,000 compared to the end of 2024 [1]